| ALUMIS INC. |
Director, 10%+ Owner |
Common Stock |
2,908,332 |
$49,441,644 |
$17.00 |
08 Jan 2026 |
Indirect |
| Gemini Therapeutics, Inc. /DE |
Director, 10%+ Owner |
Common Stock |
411,500 |
$27,837,975 |
$67.65 |
04 Oct 2021 |
Indirect |
| Quantum-Si Inc |
Director |
Class A Common Stock |
4,463,619 |
$7,900,606 |
$1.77 |
10 Jun 2021 |
Foresite Capital Fund IV, L.P. |
| Quantum-Si Inc |
Director |
Class A Common Stock |
2,342,061 |
$4,145,448 |
$1.77 |
10 Jun 2021 |
Foresite Capital Fund V, L.P. |
| Quantum-Si Inc |
Director |
Class A Common Stock |
1,598,125 |
$2,828,681 |
$1.77 |
10 Jun 2021 |
By Foresite Capital Opportunity Fund V, L.P. |
| Quantum-Si Inc |
Director |
Class A Common Stock |
20,512 |
$36,306 |
$1.77 |
11 Jun 2021 |
Direct |
| PARDES BIOSCIENCES, INC. |
President and CEO, Director, 10%+ Owner |
Common Stock |
1,000 |
$1,500 |
$1.50 |
31 Aug 2023 |
Indirect |
| Kinnate Biopharma Inc. |
Director, 10%+ Owner |
Common Stock |
0 |
$0 |
$2.59 |
03 Apr 2024 |
By Fund |
| Gemini Therapeutics, Inc. /DE |
Director, 10%+ Owner |
Stock Option (Right to Buy) |
17,245 |
|
|
04 Oct 2021 |
Direct |
| Kinnate Biopharma Inc. |
Director, 10%+ Owner |
Stock Option (right to buy) |
0 |
|
|
03 Apr 2024 |
Direct |
| PARDES BIOSCIENCES, INC. |
President and CEO, Director, 10%+ Owner |
Stock Option (Right to Buy) |
0 |
|
|
31 Aug 2023 |
Direct |